https://boards.greenhouse.io/absci- AbSci jobs
AbSci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform
AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical
drug discovery process. Our patented SoluPro® E. coli expression system and Protein Printing™ platform, informed by our deep learning Denovium Engine™, enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them
in a single efficient process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for de novo discovery, our
approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. We specialize in next-generation biologics built on complex protein scaffolds, which have proven
challenging for others to produce. With more than a dozen partnerships in place with top pharma and industry leaders, our collaborations include projects for drugs and drug candidates that range across multiple protein types and therapeutic functionality.
For more information, please visit https://www.absci.com.
Josefine Fleetwood,
(she/her/hers)
Employer Relations Manager
Oregon State University
| College of Engineering
Josefine.fleetwood@oregonstate.edu